Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab (TAK-079) Phase 1b in SLE
NCT03724916Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mezagitamab in systemic lupus erythematosus (SLE) (4 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE), Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events and 1 more. Started Nov 2018; status: completed.
02
Drugs
mezagitamab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03724916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724916.